

**(12) STANDARD PATENT  
(19) AUSTRALIAN PATENT OFFICE**

**(11) Application No. AU 2001245190 B2**

(54) Title  
**A medicinal aerosol formulation**

(51)<sup>7</sup> International Patent Classification(s)  
**A61K 009/00**

(21) Application No: **2001245190** (22) Date of Filing: **2000.12.07**

(87) WIPO No: **WO02/05784**

(30) Priority Data

(31) Number **09617328** (32) Date **2000.07.17** (33) Country **US**

(43) Publication Date: **2002.01.30**  
(43) Publication Journal Date: **2002.05.02**  
(44) Accepted Journal Date: **2005.04.07**

(71) Applicant(s)  
**Aeropharm Technology, Inc.**

(72) Inventor(s)  
**Adjei, Akwete L.; Cutie, Anthony J.**

(74) Agent / Attorney  
**Phillips Ormonde & Fitzpatrick, Level 21 367 Collins Street, Melbourne, VIC, 3000**

(56) Related Art  
**EP 518660**  
**WO 1990/009781**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 January 2002 (24.01.2002)

PCT

(10) International Publication Number  
**WO 02/05784 A1**

(51) International Patent Classification?: **A61K 9/00**

(21) International Application Number: **PCT/US00/42624**

(22) International Filing Date: 7 December 2000 (07.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/617,328 17 July 2000 (17.07.2000) US

(71) Applicant: **AEROPHARM TECHNOLOGY, INC.**  
[US/US]; 18 Mayfield Avenue, Campus Plaza, Raritan Center, Edison, NJ 08837 (US).

(72) Inventors: **ADJEI, Akwete, L.**; 15 Tillman Court, Bridgewater, NJ 08807 (US). **CUTIE, Anthony, J.**; 10 Tillman Court, Bridgewater, NJ 08807 (US).

(74) Agent: **ROSENSTOCK, Jerome**; Frommer Lawrence & Haug LLP, 745 Fifth Avenue, New York, NY 10151 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



**WO 02/05784 A1**

(54) Title: A MEDICINAL AEROSOL FORMULATION

**WO (57) Abstract:** This invention relates to a medicinal aerosol formulation and more particularly, to a medicinal aerosol formulation containing a particulate drug, a propellant and a stabilizing agent selected from an amino acid, an amino acid derivative and a mixture of the foregoing.

**TITLE OF THE INVENTION**  
**A MEDICINAL AEROSOL FORMULATION**

**Field of the Invention**

5        This invention relates to a medicinal aerosol formulation, and more particularly, to a medicinal aerosol formulation comprising a stabilizer selected from an amino acid, a derivative thereof or a mixture of the foregoing.

**Description of the Related Art**

10      Delivery of the drugs to the lung by way of inhalation is an important means of treating a variety of conditions, including such common local conditions as bronchial asthma and chronic obstructive pulmonary disease and some systemic conditions including pain management, cystic fibrosis, etc. Steroids,  $\beta$ 2 agonists, anticholinergic agents, non-steroidal anti-inflammatory agents, proteins and polypeptides are among the drugs that are administered to the lungs for such purposes. Such drugs are commonly administered to the lung in the form of an aerosol of particles of respirable size (less than about 10  $\mu\text{m}$  in diameter). In order to assure proper particle size in the aerosol, particles can be prepared in respirable size and then incorporated into a suspension

15      20      formulation containing a propellant. Alternatively, formulations can be prepared in solution form in order to avoid the concern for proper particle size in the formulation. Solution formulations must nevertheless be dispensed in a manner that produces particles or droplets of respirable size.

Once prepared an aerosol formulation is filled into an aerosol canister equipped with a metered dose valve. In the hands of the patient the formulation is dispensed via an actuator adapted to direct the dose from the valve to the patient.

It is important that an aerosol formulation be stable such that the pressurized dose discharged from the metered dose valve is reproducible.

30      Rapid creaming, settling, or flocculation after agitation are common sources of dose irreproducibility in suspension formulations. This is especially true where a binary aerosol formulation containing only medicament and propellant, e.g. 1,1,1,2-tetrafluoroethane, is employed or where such formulation contains small amounts of surfactant as well. Sticking of the valve also can cause dose

irreproducibility. In order to overcome these problems aerosol formulations often contain surfactants, which serve as suspending aids to stabilize the suspension for a time sufficient to allow for reproducible dosing. Certain surfactants also function as lubricants to lubricate the valve to assure smooth 5 actuation. Myriad materials are known and disclosed for use as dispersing aids in aerosol formulations. Suitability of materials, however, is dependent on the particular drug and the propellant or class of propellant used in the formulation.

It is sometimes difficult to dissolve sufficient quantities of conventional surfactants in hydrofluorocarbon (HFC) propellants such as HFC-134a and 10 HFC-227. Cosolvents, such as ethanol, have been used to overcome this problem, as described in U.S. Patent No. 5,225,183. An alternative approach that avoids cosolvents involves materials that are soluble in hydrofluorocarbon propellants and are said to be effective surfactants or dispersing aids in an aerosol formulation. Among such materials are certain fluorinated surfactants 15 and certain polyethyoxy surfactants.

The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general 20 knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.

## **SUMMARY OF THE INVENTION**

It has surprisingly been found that novel medicinal aerosol formulations 25 can be obtained without the use of either cosolvents, such as ethanol, or surfactants, such as sorbitan trioleate which are added to a binary aerosol formulation. Stable medicinal aerosol formulations are obtained by the use of amino acids, derivatives thereof or a mixture of the foregoing.

Accordingly to the present invention related to a medicinal aerosol 30 formulation, which comprises:

- (a) a therapeutically effective amount of a combination of at least two different particulate medicaments;
- (b) a propellant; and

(c) a stabilizer selected from an amino acid, a derivative thereof, or a mixture of the foregoing.

The present invention also relates to a method of preparing a medicinal aerosol formulation of the first aspect which comprises:

5 (a) combining (i) said combination of medicaments in an amount sufficient to provide a plurality of therapeutically effective doses, (ii) said propellant in an amount sufficient to propel a plurality of said therapeutically effective doses from an aerosol canister; and (iii) said stabilizer in an amount effective to stabilize the formulation; and

10 (b) dispersing components (i), (ii), and (iii).

The present invention further relates to a method of stabilizing a suspension aerosol formulation comprising a propellant and a combination of at least two different particulate drugs which comprises, incorporating into a formulation a stabilizer selected from the group consisting of a suitable amino acid, a derivative thereof, or any mixture of the foregoing, in an amount which is effective to prevent settling, creaming, or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.

The present invention even further relates to a metered dose inhaler  
20 containing a medicinal aerosol formulation, the formulation comprising:

(a) a combination of at least two different drugs in particulate form in a therapeutically effective amount;

(b) a propellant; and

(c) a suitable stabilizer selected from an amino acid, an amino acid derivative, or a mixture of the foregoing, present in an amount sufficient to stabilize the formulation to prevent settling, creaming or flocculation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.

### 30 DETAILED DESCRIPTION OF THE INVENTION

This invention involves a stable suspension aerosol formulation suitable for pressurized delivery which comprises (1) a particulate medicament or drug or combinations of at least two medicaments or drugs, (2) a suitable propellant, and (3) a suitable stabilizer.

2B

A suitable medicament or drug is one which is suitable for administration by inhalation, the inhalation being used for oral and nasal inhalation

therapy. Therapeutic categories of drugs or medicaments include cardiovascular drugs, antiallergics, analgesics, bronchodilators, antihistamines, antitussives, antifungals, antivirals, antibiotics, pain medicaments, antiinflammatories, peptides, proteins and steroids.

5           Particularly suitable medicaments or drugs include albuterol (also known as salbutamol), atropine, beclomethasone, esters of beclomethasone such as its monopropionate and dipropionate, budesonide, cromolyn, epinephrine, ephedrine, fentanyl, flunisolide, formoterol, ipratropium bromide, isoproterenol, pirbuterol, prednisolone, mometasone, salmeterol, amiloride, fluticasone esters, such  
10          as phosphate, monohydrate and furoate, (-)-4-amino-3,5-dichloro- $\alpha$ -[[6(2-pyridinyl)ethoxy] hexyl] amino] methyl]benzene-methanol. Also included are the suitable acid addition salts of the foregoing drugs, their hydrates and their other solvates. In this regard, suitable acid addition salts include the salts obtained from inorganic acids, such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and  
15          perchloric acids as well as organic acids such as tartaric, citric, acetic, succinic, maleic, fumaric and oxalic acids. Suitable pharmaceutically acceptable solvates include solvates with ethyl lactate, alkanes, ethers, alcohols and water.

20          An preferred embodiment of this invention are aerosol formulations which provide for a combination of at least two and most preferably no more than four different medicaments, such as cardiovascular drugs, antiallergics, analgesics, bronchodilators, antihistamines, antitussive, antifungals, antiviral, antibiotics, pain medicaments, antiinflammatories, peptides, proteins and steroids as well as the use of these aerosol formulations to treat the disease states associated with these medicaments. These medicaments and their use to treat a particular  
25          disease state are well known to practitioners of the art.

26          This invention includes the derivatives of the foregoing medicaments. These derivatives include all the salt, ester, solvate and hydrate forms of the foregoing drugs as well as their geometric and optical isomers, including their chiral forms. Such derivatives are well known to a practitioner in this art.

30          Especially preferred, are formulations which comprise combinations comprising at least two different medicants, such as  $\beta$ 2-adrenergic agonists, corticosteroids, anticholinergics and leucotriene modulators. Especially preferred

are  $\beta$ 2-adrenergic agonists, such as albuterol and formoterol, and corticosteroids, such as mometasone, hydrocortisone, fludrocortisone, dexamethasone, prednisone, cortisone, aldosterone hemi-acetal, betametasone, beclomethasone dipropionate, triamcinolone acetonide, budesonide dipropionate, fluticasone propionate and 5 fluniscolide, anticholinergics such as ipratropium bromide, histamine antagonists (mast cell modulators). Such as cromolyn, and non-steroidal antiinflammatory agents, such as acetominophen or ibuprofen.

10 The leucotrienes contemplated in this invention are those which implicated as mediators of allergic and inflammatory responses associated with bronchial asthma and rheumatoid arthritis, these medicaments are known in the art to constrict dramatically the pulmonary airways and small blood vessels. Thus, 15 inhibitors or antagonists of leucotrienes are effective mediators of the allergic responses typified by asthma and may be used to treat bronchial asthma and other diseases state associated with inflammation of the airways.

15 The leucotriene modulators contemplated in this application include, but not limited, to the following:

20 1. Inhibitors or antagonists of lecatriene, including the PAF receptor antagonists and 5-lipoxygenase inhibitors, for example 2,5-diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 2,4-diaryl tetrahydrofurans, 2,4-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes, 2,4-diaryl pyrrolidines, and 2,5-diaryl pyrrolidines, 25 triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds, 6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines (see, U.S. Patent Nos. 5,856,323; 5,358,938; 4,959,361; and 3,987,052), including, both optically pure and racemates (U.S. Patent No. 5,629,337). An example of this group of compounds is Zileuton<sup>®</sup> (Abbott Laboratories) and 30 Acolate<sup>®</sup> (Merck).

2. Chromone-2-carboxylic acid derivatives as antagonists of SRS-A (slow reacting substance of anaphylaxis (see, Samuelsson et al., Department of Chemistry, Karolinska Institutet, Stockholm, Sweden, TIPS, 227, May, 1980; J. Med. Chem. 20 371 (1977)), such as 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropoxy]-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylate (FPL 55712), which is a specific antagonist of SRS-A as well as a standard for evaluating other inhibitors;

5

10

3. Aryloxyalkyloxy-and aralkyloxy-4-hydroxy-3-nitrocoumarins as antagonists of SRS-A and inhibitors of histamine release, (see, e.g. Buckle et al., J. Med. Chem. 22 158 (1979); U.S. Patent No. 4,296,237; European Patent No. 0036663; U.S. Patent No. 4,296,120; and U.S. Patent No. 4,296,129), as well as other compounds which act as inhibitors of SRS-A including oxiranbutyric acid esters, 3-hydroxy-4-substituted-3-pyrrolidine-2,5-diones or carboxy-oxo-pyrrolidino)phenyl alkenamides and esters or (carboxyacetylamo)phenyl alkenamides and esters, or the substituted derivatives of these before mentioned compounds, including, but not limited, to alkyl, hydroxy amino, dialkylamino, hydroxymethyl, aminomethyl, alkylaminomethyl or alkanoylaminomethyl of 1 to 12 carbon atoms; -CN, -CONH<sub>2</sub> or -CO<sub>2</sub>M in which M is hydrogen, aryl, phenyl, or naphthyl, cyclohexyl, cyclopentyl, or fluoromethoxy; or

15

20

25

30

4. Antagonists and inhibitors of leukotrienes including N-o-tolylsulfonylbenzamide compounds.

All of the aforementioned prior literature is expressly incorporated by reference. These medicaments are known in the art to treat inflammatory diseases and include medicaments that block release, production, secretion, or any other biochemical action of arachidonic acid, prostaglandines, thromoxanes, or other 5 leukotrienes that participate in inflammatory reactions, exhibit chemotactic activities, stimulate lysosomal enzyme releases and act as important factors in the immediate hypersensitivity reaction.

Especially preferred medicaments include groups comprising [1-formyl-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-(hydroxycarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-((2-carboxyethyl)carbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-((2-tetrazolylethyl)carbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-(methylphenylcarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-(diphenylcarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide; [1-carbamoyl-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, and [1-(pyrrolidine-carbonyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide. Also, included are the pharmaceutically acceptable salts of these agents, including addition salts derived from organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methane sulfonic, nitric, p-toluene 20 sulfonic, acetic, citric, maleic, succinic acid, and the like. In addition, the 25 compounds in their free carboxylic acid form may be converted by standard techniques well-known to the practitioner to their corresponding alkali metal (e.g. sodium or potassium), alkaline earth metal (e.g. calcium or magnesium), ammonium or primary, secondary and tertiary alkylamine salts, the latter containing from 1 to 6 30 carbon atoms in their alkyl moieties or a pharmaceutically acceptable salt thereof. These components are known in the literature and are described, for example in Brown et al., J. Med. Chem., vol. 35(13), pp. 2419 to 2439 (1992); Jacobs et al., J.

Med. Chem., vol. 37(9), pp. 1282 to 1297 (1994); AU000646587 Australia 3/1993;

McFadden, E.R., Jr., Am. Rev. Resp. Dis., vol. 147 pp. 1306-1310 (1993);

Greenberger, P.A., Chest, vol. 101 pp. 418S-421S (1992); Lipworth, B.J.,

Pharmacol. Ther., vol. 58 pp. 173-209 (1993); Busse, W.W., Chest, vol. 104 pp.

5 1565-1571 (1993); Anonymous; Executive Summary: Guidelines for the Diagnosis and Management of Asthma, Public Health Service, Publication 91-3042A, NIH, Bethesda, MD., pp. 1-44 (1991); Israel, E., and Drazen, J.M., N. Engl. J. Med., vol., 331 pp. 737-739 (1994); or Barnes, P.J., N. Engl. Med., vol. 332 pp. 868-875 (1995). All these prior publications are expressly incorporated by reference.

10 For purposes of the formulations of this invention, which are intended for inhalation into the lungs, the medicament or drug is preferably micronized whereby a therapeutically effective amount or fraction (e.g., ninety percent or more) of the drug is particulate. Typically, the particles have a diameter of less than about 10 microns, and preferably less than about 5 microns, in order that 15 the particles can be inhaled into the respiratory tract and/or lungs.

15 The particulate medicament or drug is present in the inventive formulations in a therapeutically effective amount, that is, an amount such that the drug can be administered as an aerosol, such as topically, or via oral or nasal inhalation, and cause its desired therapeutic effect, typically preferred with one dose, 20 or through several doses. The particulate drug is administered as an aerosol from a conventional valve, e.g., a metered dose valve.


20 The term "amount" as used herein refers to quantity or to concentration as appropriate to the context. The amount of a drug that constitutes a therapeutically effective amount varies according to factors such as the potency of 25 the particular drug, the route of administration of the formulation, and the mechanical system used to administer the formulation. A therapeutically effective amount of a particular drug can be selected by those of ordinary skill in the art with due consideration of such factors. Generally a therapeutically effective amount will be from about 0.005 parts by weight to about 2 parts by weight based on 100 parts 30 by weight of the propellant.

A suitable propellant is selected. A suitable propellant is any fluorocarbon, e.g. a 1-4 hydrogen containing fluorocarbon, such as CHF<sub>2</sub>CHF<sub>2</sub>,

CF<sub>3</sub>CH<sub>2</sub>F, CH<sub>2</sub>F<sub>2</sub>CH<sub>3</sub> and CF<sub>3</sub>CHFCF<sub>3</sub>), a perfluorocarbon, e.g. a 1-4 carbon perfluorocarbon, (such as CF<sub>3</sub>CF<sub>3</sub>, CF<sub>3</sub>CF<sub>2</sub>CF<sub>3</sub>); or any mixture of the foregoing, having a sufficient vapor pressure to render them effective as propellants. Some typical suitable propellants include conventional chlorofluorocarbon (CFC)

5 propellants such as mixtures of propellants 11, 12 and 114. Non-CFC propellants such as 1,1,1,2-tetrafluoroethane (Propellant 134a), 1,1,1,2,3,3,3-heptafluoropropane (Propellant 227) or mixtures thereof are preferred. The propellant is preferably present in an amount sufficient to propel a plurality of the selected doses of drug from an aerosol canister.

10 A suitable stabilizer is selected. A suitable stabilizer includes (1) an amino acid selected from (a) a monoamino carboxylic acid of the formula, H<sub>2</sub>N-R-COOH (I), (b) a monoamino dicarboxylic acid of the formula, H<sub>2</sub>N-R(COOH)<sub>2</sub> (II) and (c) a diamino monocarboxylic acid of the formula (H<sub>2</sub>N)<sub>2</sub>-R-COOH (III), where R is a straight or branched alkyl radical of from 1 to 22 carbon atoms, which can be 15 mono or poly-substituted with moieties such as sulfide (-S-), oxide (-O-), hydroxyl (-OH), amide (-NH), sulfate (-SO<sub>4</sub>); aryl of the formula



where X is hydrogen, halogen (F, Cl, Br, I), alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, hydroxy and nitro; and heterocyclic, such as thienyl, furyl, 20 pyranyl, imidazolyl, pyrrolyl, thizolyl, oxazolyl, pyridyl, and pyrimidinyl compounds; (2) a derivative of the amino acid selected from (a) acid addition salts of the amino group, obtained from inorganic acids, such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, and perchloric acids, as well as organic acids, such as tartaric, citric, acetic, succinic, maleic, fumaric, oxalic acids; (b) 25 amides of the carboxylic acid group, e.g., glutamine, (c) esters of the carboxylic acid group obtained from aliphatic straight or branched chain alcohols of from 1 to 6 carbon atoms, e.g. L-aspartyl-L-phenylalanine methylester (Aspartame®), and (3) a mixture of the amino acid and the derivative of the amino acid.

30 Suitable amino acids of the formula I include glycine, glycine, alanine, valine, leucine, isoleucine, methionine, threonine, isovaline, phenylalanine, tyrosine,

serine, cysteine, N-acetyl-L-cysteine, histidine, tryptophan, proline, and hydroxyproline, e.g. trans-4-hydroxy proline. Compounds of the formula II include, aspartic acid, and glutamic acid, compounds of the formula (III) include arginine, lysine, hydroxylysine, ornithine, asparagine, and citrulline.

5 An aerosol formulation preferably comprises the stabilizer in an amount effective to stabilize the formulation relative to an identical formulation not containing the stabilizer, such that the drug does not settle, cream or flocculate after agitation so quickly as to prevent reproducible dosing of the drug. Reproducible dosing can be achieved if the formulation retains a substantially uniform drug 10 concentration for about two or three seconds after agitation.

The particular amount of stabilizer that constitutes an effective amount is dependent upon the particular stabilizer, the particular propellant, and on the particular drug used in the formulation. It is therefore not practical to enumerate specific effective amounts for use with specific formulations of the invention, but 15 such amounts can readily be determined by those skilled in the art with due consideration of the factors set forth above. Generally, however, the stabilizer can be present in a formulation in an amount from about 0.000002 percent by weight, to about 20% by weight, more preferably about 0.0002 percent to about 10% by weight, based on the weight of the formulation.

20 It has surprisingly been found that the formulation of the invention is stable without the necessity of employing a cosolvent, such as ethanol, or surfactants. However, further components, such as conventional lubricants or surfactants, cosolvents, ethanol, etc., can also be present in an aerosol formulation of the invention in suitable amounts readily determined by those skilled in the art. In 25 this regard, reference is made to U.S. Patent No. 5,225,183, which is incorporated by reference hereinto in its entirety.

Generally the formulations of the invention can be prepared by combining (i) the drug in an amount sufficient to provide a plurality of therapeutically effective doses; (ii) the stabilizer in an amount effective to stabilize 30 each of the formulations; (iii) the propellant in an amount sufficient to propel a plurality of doses from an aerosol canister; and (iv) any further optional components e.g. ethanol as a cosolvent; and dispersing the components. The components can be

dispersed using a conventional mixer or homogenizer, by shaking, or by ultrasonic energy. Bulk formulation can be transferred to smaller individual aerosol vials by using valve to valve transfer methods, pressure filling or by using conventional cold-fill methods. It is not required that a stabilizer used in a suspension aerosol

5 formulation be soluble in the propellant. Those that are not sufficiently soluble can be coated onto the drug particles in an appropriate amount and the coated particles can then be incorporated in a formulation as described above.

Aerosol canisters equipped with conventional valves, preferably metered dose valves, can be used to deliver the formulations of the invention. It has

10 been found, however, that selection of appropriate valve assemblies for use with aerosol formulations is dependent upon the particular stabilizer and other adjuvants used (if any), on the propellant, and on the particular drug being used. Conventional neoprene and buna valve rubbers used in metered dose valves for delivering conventional CFC formulations often have less than optimal valve delivery

15 characteristics and ease of operation when used with formulations containing HFC-134a or HFC-227. Therefore certain formulations of the invention are preferably dispensed via a valve assembly wherein the diaphragm is made of a nitrile rubber such as DB-218 (American Gasket and Rubber, Schiller Park, Ill.) or an EPDM rubber such as Vistalon<sup>TM</sup> (Exxon), Royalene<sup>TM</sup> (UniRoyal), bunaEP (Bayer). Also

20 suitable are diaphragms fashioned by extrusion, injection molding or compression molding from a thermoplastic elastomeric material such as FLEXOMER<sup>TM</sup> GERS 1085 NT polyolefin (Union Carbide).

Conventional aerosol canisters, coated or uncoated, anodized or unanodized, e.g., those of aluminum, glass, stainless steel, polyethylene

25 terephthalate, and coated canisters or cans with epon, epoxy, etc., can be used to contain a formulation of the invention.

The formulation of the invention can be delivered to the respiratory tract and/or lung by oral inhalation in order to effect bronchodilation or in order to treat a condition susceptible of treatment by inhalation, e.g., asthma, chronic

30 obstructive pulmonary disease. The formulations of the invention can also be delivered by nasal inhalation in order to treat, e.g., allergic rhinitis, rhinitis, (local) or

diabetes (systemic), or they can be delivered via topical (e.g., buccal) administration in order to treat, e.g., angina or local infection.

Throughout the description and the claims of this specification the word "comprise" and variations of the word, such as "comprising" and "comprises" is  
5 not intended to exclude other additives, components, integers or steps.

## Claims:

1. A medicinal aerosol formulation, which comprises:
  - (a) a therapeutically effective amount of a combination of at least two different particulate medicaments;
  - 5 (b) a propellant; and
  - (c) a stabilizer selected from an amino acid, a derivative thereof, or a mixture of the foregoing.
2. The formulation as defined in claim 1 wherein said stabilizer is selected from the group consisting of glycine, glycine, alanine, valine, leucine, isoleucine, methionine, threonine, isovaline, phenylalanine, tyrosine, serine, histidine, tryptophan, proline, hydroxyproline, arginine, ornithine, asparagine, citrulline, aspartic acid, cysteine, glutamic acid, glutamine, lysine, hydroxylysine, N-acetyl-L-cysteine, phenylalanine, trans-4-hydroxy-L-proline, tyrosine, L-aspartyl-L-phenylalanine methylester and a mixture of any of the foregoing.
- 15 3. The formulation as defined in claim 1 wherein the medicaments for the combination are selected from the group consisting of  $\beta$ -2 adrenergic agonists, corticosteroids, anticholinergics, histamine antagonists, non-steroidal antiinflammatory agents and leucotriene modulators.
4. The formulation as defined in claim 3, wherein the stabilizer is selected from the group consisting of glycine, glycine, alanine, valine, leucine, isoleucine, methionine, threonine, isovaline, phenylalanine, tyrosine, serine, histidine, tryptophan, proline, hydroxyproline, arginine, ornithine, asparagine, citrulline, aspartic acid, cysteine, glutamic acid, glutamine, lysine, hydroxylysine, N-acetyl-L-cysteine, phenylalanine, trans-4-hydroxy-L-proline, tyrosine, L-aspartyl-L-phenylalanine methylester and a mixture of any of the foregoing
- 20 5. The formulation as defined in claim 3 wherein the  $\beta$ 2 adrenergic agonist are albuterol, formoterol or the pharmaceutically acceptable salts, esters, hydrates, solvates or geometric or optical isomers of the foregoing.
6. The formulation as defined in claim 3 wherein the corticosteroids are selected from the group consisting of mometasone, hydrocortisone, fludrocortisone, dexamethasone, prednisone, cortisone, aldosterone hemi-acetal, betametasone, beclomethasone dipropionate, triamcinolone acetonide,

budesonide dipropionate, fluticasone propionate, fluniscolide, the pharmaceutically acceptable salts, esters, hydrates, solvates and geometric or optical isomers of the foregoing and a mixture of any of the foregoing medicaments used.

7. The formulation as defined in claim 3 where the  
5 anticholinergics agent is cromolyn and the antiinflammatory agent is acetominophen or ibuprofen.
8. The formulation as defined in claim 3 wherein the leudotriene modulator is selected from the group consisting of [[1-formyl-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-  
10 tolylsulfonylbenzamide, [1-(hydroxycarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, [1-((2-carboxyethyl)carbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide; [1-((2-tetrazolylethyl)carbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-  
15 tolylsulfonylbenzamide; [1-(methylphenylcarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide; [1-(diphenylcarbamoyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide; [1-carbamoyl-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-  
20 tolylsulfonylbenzamide; and [1-(pyrrolidine-carbonyl)-5-(cyclopentyloxycarbonyl)amino-1H-indol-3-ylmethyl]-3-methoxy-N-o-tolylsulfonylbenzamide, the pharmaceutically acceptable salts of the forgoing, and a mixture of any of the foregoing medicaments.
9. The formulation as defined in claim 1, wherein combination  
25 comprises of a corticosteroid and  $\beta$ 2-adrenergic agonist;
10. The formulation as defined in claim 1, wherein the combination comprises a corticosteroid and an anticholinergic agent;
11. The formulation as defined in claim 1, wherein the combination comprises of a corticosteroid and a leucotriene modulator;
- 30 12. The formulation as defined in claim 1, wherein the combination comprises of a corticosteroid, a  $\beta$ -2 adrenergic agonist and a leucotriene modulator;

13. The formulation as defined in claim 9, wherein the corticosteroid is fluticasone or fluticasone propionate;

14. The formulation as defined in claim 1 wherein the combination comprises a  $\beta$ -2 adrenergic agonist and a leucotriene modulator or a  $\beta$ -2 adrenergic agonist and a anticholinergic.

15. The formulation as defined in claim 1, wherein the combination comprises a histamine antagonist or an antiinflammatory agent.

16. The formulation as defined in claim 1, wherein said propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane or a mixture thereof.

17. The formulation as defined in claim 4, which further includes a cosolvent.

18. The formulation as defined in claim 17 wherein said cosolvent comprises ethanol.

19. The formulation as defined in claim 2 wherein said stabilizer is present in an amount effective to prevent settling, creaming or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.

20. The formulation as defined in claim 19 wherein said stabilizer is present in an amount ranging from about 0.000002% by weight to about 20% by weight based on the weight of the formulation.

21. A method of preparing a medicinal aerosol formulation according to claim 1, which comprises:

(a) combining (i) said combination of medicaments in an amount sufficient to provide a plurality of therapeutically effective doses, (ii) said propellant in an amount sufficient to propel a plurality of said therapeutically effective doses from an aerosol canister; and (iii) said stabilizer in an amount effective to stabilize the formulation; and

(b) dispersing components (i), (ii) and (iii).

22. The method as defined in claim 21 wherein the medicinal aerosol formulation further comprises combining in step (a) a cosolvent and in step (b) dispersing components (i), (ii), (iii) with said cosolvent.

23. A method of treating in an animal a condition capable of treatment by oral or nasal inhalation, which comprises, administering a formulation according to claim 1 to said animal by oral or nasal inhalation.

24. A formulation according to claim 1 in an aerosol canister 5 equipped with a metered dose valve.

25. A method of stabilizing a suspension aerosol formulation comprising a propellant and a combination of at least two different particulate drugs which comprises,

incorporating into the formulation a stabilizer selected from the group 10 consisting of a suitable amino acid, a derivative thereof, or any mixture of the foregoing, in an amount which is effective to prevent settling, creaming, or flocculation of the formulation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.

26. A metered dose inhaler containing a medicinal aerosol 15 formulation, the formulation comprising:

(a) a combination of at least two different drugs in particulate form in a therapeutically effective amount;

(b) a propellant; and

(c) a suitable stabilizer selected from an amino acid, an amino 20 acid derivative, or a mixture of the foregoing, present in an amount sufficient to stabilize the formulation to prevent settling, creaming or flocculation for a time sufficient to allow reproducible dosing of the drug after agitation of the formulation.

27. The metered dose inhaler as defined in claim 26 wherein the stabilizer is selected from the group consisting of glycine, glycine, alanine, valine, 25 leucine, isoleucine, methionine, threonine, isovaline, serine, histidine, tryptophan, proline, hydroxyproline, arginine, ornithine, asparagine, citrulline, aspartic acid, cysteine, glutamic acid, glutamine, lysine, hydroxylysine, N-acetyl-L-cysteine, phenylalanine, trans-4-hydroxy-L-proline, tyrosine, L-aspartyl-L-phenylalanine methylester and a mixture of any of the foregoing.

30 28. The metered dose inhaler as defined in claim 26 wherein said stabilizer is present in an amount of 0.000002% by weight to about 20% by weight based on the weight of the medicinal aerosol formulation.

29. The metered dose inhaler as defined in claim 26, where in the medicaments for the combination are selected from the group consisting of  $\beta$ -2 adrenergic agonists, corticosteroids, anticholorergics, and leucotriene modulators.

5 30. The metered dose inhaler as defined in claim 26, wherein the propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane or a mixture thereof.

31. The metered dose inhaler as defined in claim 26, wherein the medicinal aerosol formulation further comprises a cosolvent.

10 32. The metered dose inhaler as defined in claim 31, wherein said cosolvent comprises ethanol.

33. A medicinal aerosol formulation of any one of claims 1 to 20 or claim 24 substantially as herein described with reference to any one of the Examples.

15 34. A method of claim 21 or claim 22 of preparing a medicinal aerosol formulation which method is substantially as herein described with reference to any one of the Examples.

35. A medicinal aerosol formulation whenever prepared by the method of claim 21, 22 or 34.

20 36. A method of claim 23 of treating in an animal a condition capable of treatment by oral or nasal inhalation which method is substantially as herein described with reference to any one of the Examples.

25 37. A method of claim 25 of stabilizing a suspension aerosol formulation which method is substantially as herein described with reference to any one of the Examples.

38. A metered dose inhaler of any one of claims 26 to 32, substantially as herein described with reference to any one of the Examples.

Dated: 19 August, 2004

30 PHILLIPS ORMONDE & FITZPATRICK

Attorneys for:

KOS PHARMACEUTICALS, INC.